Latest News and Press Releases

Failover completed to Site B The Failover to Site B has been completed; participants are now able to login to Site B.   Please remember to communicate your results to us! For questions...

  Failover completed to Site B The Failover to Site B has been completed; participants are now able to login to Site B.   Please remember to communicate your results to us! For...

Failover completed to Site B The Failover to Site B has been completed; participants are now able to login to Site B.   Please remember to communicate your results to us! For questions...

Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over  24 weeks of active treatment[1] Omalizumab 300 mg was...

  Failover initiated NASDAQ OMX has initiated the failover from Site A to Site B. A message will follow confirming Site B availability.   For questions or comments, please...

  Failover initiated NASDAQ OMX has initiated the failover from Site A to Site B. A message will follow confirming Site B availability.   For questions or comments, please...

  Failover initiated NASDAQ OMX has initiated the failover from Site A to Site B. A message will follow confirming Site B availability.   For questions or comments, please...

  Today’s failover test in Genium INET Production As communicated in IT Notices 61/13, 63/13 , 68/13 and 75/13 NASDAQ OMX Nordic will today perform verification tests of the...

    2013-10-05       Today’s failover test in Genium INET Production As communicated in IT...

   2013-10-05         Today’s failover test in Genium INET Production As communicated in...